Avelumab Plus Intermittent Axitinib in Previously Untreated Patients with Metastatic Renal Cell Carcinoma. The Tide-A Phase 2 Study-Reference-Cited by-同舟云学术

Avelumab Plus Intermittent Axitinib in Previously Untreated Patients with Metastatic Renal Cell Carcinoma. The Tide-A Phase 2 Study

Published:2024-03 Issue: Volume: Page:
ISSN:0302-2838
Container-title:European Urology
language:en
Short-container-title:European Urology

Author:

Iacovelli Roberto^ORCID,Ciccarese Chiara,Buti Sebastiano,Zucali Paolo Andrea,Fantinel Emanuela,Bimbatti Davide,Verzoni Elena,Accettura Caterina,Bonomi Lucia,Buttigliero Consuelo,Fornarini Giuseppe,Pipitone Stefania,Atzori Francesco,Masini Cristina,Massari Francesco,Primi Francesca,Strusi Alessandro,Giudice Giulia Claire,Perrino Matteo,Maruzzo Marco,Milella Michele,Giannarelli Diana,Brunelli Matteo,Procopio Giuseppe,Tortora Giampaolo

Funder

Merck

Merck KGaA

Pfizer Inc

Publisher

Elsevier BV

Reference17 articles.

1. Cancer facts & figures 2023;American Cancer Society,2023

2. Systemic therapy for metastatic renal-cell carcinoma;Choueiri;N Engl J Med,2017

3. European Society of Medical Oncology. Clinical practice guidelines – renal cell carcinoma. https://www.esmo.org/guidelines/guidelines-by-topic/genitourinary-cancers/renal-cell-carcinoma

4. EAU. Guidelines for renal cell carcinoma. Paper presented at: The EAU Annual Congress; March 10–13, 2023; Milan. https://uroweb.org/guidelines/renal-cell-carcinoma/chapter/citation-information

5. Avelumab plus axitinib versus sunitinib for advanced renal-cell carcinoma;Motzer;N Engl J Med,2019

Cited by 1 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Anti-VEGF and -PD-1 Combinations in Renal Cell Carcinoma: When Are Treatment Breaks Safe?;European Urology;2024-06